Abstract
A transversal study based on 1,186 respondents’ group questioning was realized in order to study lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) prevalence in men from the Republic of Moldova. The basic tools used included IPSS (International Prostate Symptom Score) and IIEF-5 (International Index of Erectile Function) questionnaires as well as general questions to assess the presence of risk factors.
ED total prevalence in the studied population was 47.1%, inclusively mild form - 22%, slightly moderate - 12.4%, moderate - 7.6% and severe - 51%.
The overall prevalence of LUTS symptoms, according to the IPSS score, was 42.9% with significant variations in males up to 40 years - 15.7% and over this age - 62.6% (p <0.05). LUTS presence correlates directly with erectile dysfunction prevalence, especially in men over the age of 40, where 82% of those with LUTS will also have ED.
LUTS and ED symptomatologies have an increased prevalence among men from the Republic of Moldova, especially over the age of 40. Statistically significant correlations between these two pathologies were demonstrated. These correlations need to be taken into account both in diagnosis establishment and in concomitant treatment.
Keywords: lower urinary tract symptoms, erectile dysfunction, men’s health, correlation
Introduction
Erectile dysfunction (ED) affects about half of men over the age of 50. At the same time, clinical manifestations of urinary tract diseases, such as nocturnal pollakiuria, strangury, dysuria, along with others are manifested more frequently after this age. Epidemiological studies show direct correlations between erectile dysfunction and lower urinary tract symptoms (LUTS), regardless of age or other comorbidities such as diabetes or high blood pressure. However, until now it has not been established with certainty whether erectile dysfunction is a consequence of low urinary symptomatology or, conversely, LUTS symptomatology appears as an erectile dysfunction. The existence of a direct association between erectile dysfunction and LUTS, considering that both have the age as a common point, was confirmed by both epidemiological studies and explanations of pathophysiological mechanisms at the beginning of the 21st century.
The first studies on the correlations between LUTS and erectile dysfunction showed that 72% of men with ED suffer concomitantly from lower urinary symptomatology [1][2].
The MSAM-7 study (Multinational Survey of Aging Male), which took place in the US and six European countries, included 12,815 patients aged between 50 and 80. About 90% of respondents reported LUTS symptoms, but only 19% have sought medical consultation, and only 11% followed treatment. One of the main findings of the study was that LUTS severity is a major risk factor for sexual dynamic dysfunction disorders affecting primarily the erectile component [1][2].
Subsequent studies, including large groups, confirmed this interdependence. Wein showed on a group of 2,954 patients with a global prevalence of erectile dysfunction in patients with LUTS of 49%, but LUTS severity was a strong erectile dysfunction predictor of 8.90 (p <0.05) probability ratio. LUTS presence or its change to a higher severity category has a greater impact on erectile function compared with 10 years of aging, but about 24.8% of patients have no sexual activity because of LUTS [3].
In 2012, Seftel published a meta-analysis based on 23 relevant scientific studies, which showed that up to that moment there were few population surveys that used IPSS and IIEF questionnaires assessing global prevalence and correlations between diseases. However, based on some alternative evaluations, it was established that among the general male population between 13-29% had moderate to severe LUTS symptomatology, but 8-35% had ED from moderate to severe. The coexistence between LUTS and ED of any severity was 71-80% of men who requested treatment for LUTS. These correlations increase with age ranging from 59-86% in men aged 40-60 years and from 79 to 100% in men over 50 years of age [4].
Most studies conducted up to 2000 accentuated a single risk factor for LUTS and erectile dysfunction – the age. The following studies, including recent ones, showed that several risk factors are similar in both situations, especially metabolic syndrome, hormonal disturbances, diabetes and others. It is certain that both situations share at least four pathophysiological mechanisms: change in bioavailability of nitric oxide, alpha adrenergic receptor hyperactivity, pelvic atherosclerosis and sexual hormones disorder [5].
Due to the fact that causal mechanisms are common, it was proposed that the men who require consultation for pathology be investigated in conjunction with the mandatory assessment of sexual function. On the other hand, more clinical studies showed LUTS improvement after the administration of phosphodiesterase-5 inhibitors. However, in cases of testosterone deficiency, its administration may have a therapeutic role in LUTS treatment [6][7].
At the same time, there are still gaps that make it challenging to perform comparative studies, starting with the standardization of terminology, different methods of assessing the clinical situations and, in particular, different treatment concepts [8].
Therefore, the association between LUTS and erectile dysfunction is a problem of contemporary urology with many unknown uncertainties.
Purpose of the study: To assess the prevalence of lower urinary symptoms and the possible correlations between it and erectile dysfunction in men from the Republic of Moldova.
Material and methods
A transversal descriptive study was conducted between 2015 and 2016, on the basis of representative sample questionnaire of 1,186 males aged between 18-80 years. The mean age of the subjects enrolled in the study was 47.8 years. LUTS symptomatology presence was determined by completing the answers to questions that characterize micturition, as well as validated IPSS questionnaires, which determine the presence and severity of low urinary complaints specific to the presence of benign prostatic hypertrophy, prostate cancer or inflammatory diseases of the prostate and urethra. The presence of erectile dysfunction was confirmed using the IIEF-5 (International Index of Erectile Function) questionnaire.
The study design was approved by the Research Ethics Committee of the SUMPh "Nicolae Testemitanu", Chisinau, Republic of Moldova.
The data were processed using the statistical software package SPSS 21. The descriptive, comparative (Student t-test) and Pearson’s R correlation coefficient statistics were used. The significant threshold for comparisons was set at 5% (p <0.05).
Results
From 1,186 investigated men, 626 (52.8%) reported the complete absence of low urinary complaints, but 560 (47.2%) had at least one complaint. The most common reported urinary complaint was nocturia, present in about 41% of men, followed by the need to force urination, 20.4% and frequent urination in less than 2 hours from the last urination in 18.5%, 190 people (16%) reported the incomplete discharge of bladder or residual urine, characteristic to the presence of infra bladder obstruction. At the same time, 83 (7%) respondents reported the presence of being a characteristic to an inflammatory process. The prevalence of lower urinary tract symptoms is statistically different in subjects up to 40 years of age, where about 122 patients (23.4%) reported the occurrence of some complaints, especially irritating ones, and over this age, when about 438 people, 65.9% people reported the presence of urinary complaints, including obstructive ones (p <0.05). The prevalence of some LUTS symptoms is presented in Table 1.
Table 1.
The presence of complaints characteristic to low urinary symptomatology (1,186 respondents)
| Under 40 years | Over 40 years | Total | ||||
|---|---|---|---|---|---|---|
| Age | ||||||
| Complaint | n | % | n | % | n | % |
| Incomplete emptying feeling | 29 | 5.6% | 161 | 24% | 190 | 16% |
| Frequent urination: less than 2 hours since the last urination | 38 | 7.3% | 181 | 27.2 % | 219 | 18.5% |
| Difficulty to postpone urination or urine loss | 6 | 1.2% | 76 | 11.4% | 82 | 6.9% |
| Urinary intermittency | 12 | 2.4% | 78 | 11.7% | 90 | 7.6% |
| Weak urinary jet | 21 | 4 % | 196 | 29.5 % | 217 | 18.3% |
| Necessity to force urination | 27 | 5.2 % | 215 | 32.3% | 242 | 20.4 % |
| Nocturia | 76 | 14.6% | 412 | 62% | 488 | 41.1% |
| Testicular, penile, perineal pain. | 26 | 5% | 48 | 7.2% | 74 | 6.2% |
| Burning sensation with urination | 27 | 5.2% | 48 | 7.2% | 75 | 6.3% |
| Any symptom ofthose enumerated | 262 | 0.5 complaints per male | 1.415 | 2.2 complaints per male | 1.677 | 1.4 complaints per male |
A lot of respondents reported the existence of many overlapping complaints, but as it is shown in the table, the average number of complaints per respondent can be 0.5 for a man under 40 and about 2.2 for a man over this age.
For a more objective assessment of low urinary complaints, the benchmark is the IPSS score. The IPSS score is primarily specific to prostate pathologies and is based on summarizing the patient's answers to 7 questions that characterize urination, but the 8th question refers to the quality of life. Questions describe bladder emptying, urinary frequency, urinary excretion and urine flow, etc. Each question has several response choices with a definite score, following the calculation of the score, as recommended by the American Urology Association (AUA), prostate symptomatology classifies as mild, medium and severe. The mild symptomatology corresponds to an IPSS score of up to 7, but the quality of life, QoL index up to 2. For the mean symptomatology, the IPSS index is greater than 7 but less than 19, and for a severe symptomatology, the IPSS is greater than 20, QoL for both being greater than 2.
The IPSS score has a higher degree of accuracy in the urological patient's assessment and is therefore both clinically and scientifically relevant. Typically, in the case of mild IPSS, the therapy is under the family doctor's observation, but medium and severe IPSS compulsorily implies more detailed urological assessment.
Following the assessment of responses, the IPSS score was present in men aged 40 years and older in 82 participants (15.8%), most of them with slight, significantly lower degree compared to those aged 40 years and over, where 416 (62.6%) persons experienced IPSS symptomatology, and over 65, about 86% of people had IPSS complaints (Table 2).
Table 2.
The presence of low urinary complaints according to the IPSS score
| Age (years) | IPSS mild | IPSS medium | IPSS severe | Total | ||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | |
| 18 – 29 | 15 | 5.8% | 5 | 2% | 0 | - | 20 | 7.8% |
| 30 – 39 | 38 | 15.6% | 14 | 5.4% | 10 | 3.8% | 62 | 24% |
| 40 – 49 | 64 | 23.6% | 23 | 8.8% | 17 | 6.5% | 104 | 38.7% |
| 50 – 64 | 118 | 41% | 57 | 19.9% | 45 | 15.8% | 220 | 76% |
| 65 | 24 | 22.4% | 37 | 34.6% | 31 | 30% | 92 | 86% |
| Total | 259 | 21.8% | 136 | 11.7% | 103 | 8.9% | 498 | 42.9% |
The difference between the number of men who were evaluated according to IPSS criterion and those who had low urinary complaints is explained by the fact that the complaints characteristic to chronic prostatitis such as pain or urination burning sensation are part of chronic prostatitis index NIH CPSI.
Erectile function was evaluated according to the IIEF-5 questionnaire validated to assess the prevalence of the disease. According to the international index of erectile function, the total prevalence of erectile dysfunction was reported in 47.1% of the population, with a difference between the age groups, 17.3% in patients up to 30 years and 88.8% in ones over 65 years old (P <0.001) (Table 3). Also, the prevalence of severe erectile dysfunction is significantly higher in older men, 30.8% in those over 65, compared to 0.7% in those aged up to 30 years (P <0.001).
Table 3.
Prevalence and manifestation degree of erectile dysfunction in age groups
| ED presence and degree | Age (years) | Total | ||||
|---|---|---|---|---|---|---|
| 18-29 | 30-39 | 40-49 | 50-64 | >65 | ||
| Severe | 2 (0.7%) | 3 (1.2%) | 6(2.2%) | 17 (5.9%) | 33 (30.8%) | 61 (5.1%) |
| Moderate | 4 (1.4%) | 7(2.7%) | 15 (5.5%) | 45 (15.7%) | 19 (17.8%) | 90 (7.6%) |
| Slightly moderate | 8 (3.0%) | 15 (5.8%) | 38 (14.0%) | 63 (22%) | 23 (21.5%) | 147 (12.4%) |
| Mild | 31 (11.9%) | 45 (17.3%) | 82 (30.2%) | 83 (28.9 %) | 20 (18.7%) | 261 (22%) |
| Without erectile dysfunction | 216 (82.7%) | 190 (73%) | 130 (48%) | 79(27.5%) | 12 (11.2%) | 627 (52.9%) |
| Total | 261 | 260 | 271 | 287 | 107 | 1.186 |
Erectile dysfunction prevalence in men with few urinary complaints was analyzed.
In the first stage, we evaluated the presence of erectile dysfunction in patients with nocturnal pollakiuria. Nocturnal pollakiuria is one of the most significant symptoms characteristic of a urinary tract disorder, but also neurological or cardiovascular disorders. Normally, it is absent or accepted once, but only at certain times and conditions. As mentioned previously, 698 men or about 59% reported the absence of night-time urination. In this group, erectile dysfunction was present in 32.7% of people. At the other end, there are 201 people who reported 2, 3 or more night-time urinations. In this group the prevalence of erectile dysfunction was 86% (P<0.001) (Table 4).
Table 4.
Prevalence and severity degree of ED in men who reported nocturnal pollakiuria
| Symptoms | Without nocturnal urination | Nocturnal urination once | Nocturnal urination twice | 3 and more nocturnal urinations | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | |
| Severe ED | 9 | 1.1% | 16 | 5.6 % | 18 | 11.8% | 18 | 37,5% | 61 | 5,2% |
| Moderate ED | 21 | 2.4% | 23 | 8 % | 37 | 24.1% | 9 | 18,8% | 90 | 7,6% |
| Easily moderate ED | 50 | 7.2% | 49 | 17.1% | 41 | 26.8% | 7 | 14,6% | 147 | 12,4% |
| Mild ED | 145 | 20.8% | 72 | 24.9% | 33 | 21.5% | 10 | 20,8% | 261 | 23% |
| Without ED | 473 | 67.3% | 127 | 44.3% | 24 | 17.9% | 4 | 8,3% | 627 | 52,9% |
| Total | 698 | 287 | 153 | 48 | 1.186 | |||||
There is a direct dependence between presence and degree of manifestation of nocturnal pollakiuria and erectile dysfunction. Of the patients who have no night urination, only about 1% will have severe erectile dysfunction, compared to 37.5% of those with nocturnal pollakiuria, and only 8.3% of patients will have no erectile dysfunction at all.
At the same time, nocturnal pollakiuria is only a symptom of LUTS, which does not fully reflect the severity of the disease, the IPSS score being much more relevant. Therefore, the prevalence and extent of erectile dysfunction in correlation with the IPSS score were determined. In 688 patients reporting the absence of urinary symptomatology (with negative IPSS), erectile dysfunction was present in 177 subjects (25.7%), among them in mild form. From 498 men with a current IPSS score, only 23.3% did not have erectile dysfunction (p <0.05). The presence and severity of erectile dysfunction depend on the severity of IPSS. In 239 subjects with an IPSS score higher than 8, erectile dysfunction was present in 207 (86.6%), of which only in 23.2% a mild form, but in patients with severe IPSS, only 2.9% did not have erectile dysfunction, compared with 32.4% in those with mild IPSS, or 74.3% (p <0.05) who did not generally report urinary symptomatology (Table 5).
Table 5.
Prevalence and severity degree of erectile dysfunction according to the IPSS score
| IIEF. n(%) | ||||||
|---|---|---|---|---|---|---|
| IPSS | Severe | Moderate | Slightly moderate | Mild | Without ED | Total |
| Without IPSS | 3 (0.43%) |
10 (1.5%) |
35 (5.1%) |
129 (18.8%) |
511 (74.3%) |
688 |
| IPSS present | 58 (11. 6%) |
80 (16.1%) |
112 (22.5 %) |
132 (26.5%) |
116 (23.3%) |
498 |
| Mild | 14 (5.4%) |
24 (9.3%) |
53 (20.5%) |
84 (32.4%) |
84 (32.4%) |
259 |
| Moderate | 17 (12.5%) |
25 (18.4%) |
38 (28%) |
27 (19.9%) |
29 (21.3%) |
136 |
| Severe | 27 (26.2%) |
31 (30.1%) |
21 (20.4%) |
21 (20.4%) |
3 (2.9%) |
103 |
| Total | 61 (5.1%) |
90 (7.6%) |
147 (12.4%) |
261 (22%) |
627 (52.9%) |
1.186 |
We also analyzed the presence of erectile dysfunction in patients with age-related LUTS symptomatology. To simplify the interpretation of the results, we divided the respondents into two groups, up to 40 years old and older than 40 (Table 6). Thus, in patients up to 40 years old, IPSS symptomatology was present in 82 males (15.2%) and absent in 439 (84.8%). There were no signs of erectile dysfunction in men with IPSS of 41 (45%), and in those with ED - 9 men (10.9%) reported moderate or severe dysfunction that is significantly higher compared to those without IPSS, 1.6%, but much lower than in people over 40. Thus, 416 (62.6%) of people over the age of 40, who reported an IPSS score presence, only 18% did not report ED. So at a young age, in the absence of other risk factors, only the presence of IPSS correlates less with ED compared with elderly men.
Table 6.
Prevalence and severity degree of erectile dysfunction depending on IPSS presence and age
| Age | IPSS | IIFE – 5 | Total | |||||
|---|---|---|---|---|---|---|---|---|
| severe | moderate | Slightly moderate | Mild | Without ED | ||||
| Under 40 | Absent IPSS | n | 2 | 5 | 9 | 58 | 365 | 439 |
| % | 0.5% | 1.1% | 2.1% | 13.2% | 83.1 % | 84,2% | ||
| Present IPSS | n | 3 | 6 | 14 | 18 | 41 | 82 | |
| % | 3.6% | 7.3% | 17.1% | 22% | 50% | 8% | ||
| Total | n | 5 | 11 | 23 | 76 | 406 | 521 | |
| % | 1% | 2.1% | 4.4% | 14.6% | 77.9% | |||
| Over 40 | IPSS Absent | n | 1 | 5 | 26 | 71 | 146 | 249 |
| % | 0.4% | 2% | 10.4% | 28.5% | 58.6% | 37,4% | ||
| IPSS Present | n | 55 | 74 | 98 | 114 | 75 | 416 | |
| % | 13.2% | 17.8% | 23.6% | 27.4% | 18% | 62,6 % | ||
| Total | n | 56 | 79 | 124 | 185 | 221 | 665 | |
| % | 8.4% | 11.9% | 18.3% | 26.5 % | 33.4% | |||
| Total | 61 | 90 | 147 | 261 | 627 | 1.186 | ||
The severity of IPSS in elderly men will more evidently influence erectile dysfunction. Thus, severe or moderate ED will have about 30.1% of men with present IPSS, compared with 2.4% men whose urinary symptomatology is absent.
The presence of an IPSS score in young people is mostly owed to urethritis or prostatitis and does not directly contribute, at least during initial stages of disease manifestation, to the occurrence of an erectile dysfunction, especially if it is of an easy or moderate degree.
Correlations between IPSS severity and ED degree were also studied and presented in Table 7.
Table 7.
Prevalence and degree of IPSS and erectile dysfunction depending on age
| IIFE – 5 | |||||||
|---|---|---|---|---|---|---|---|
| Age | IPSS | Total | |||||
| Severe | Moderate | Slightly moderate | Mild | Without ED | |||
| Under 40 | Without IPSS | 2 (0.5%) | 5 (1.1 %) | 9 (2.1%) | 58 (13.2%) | 365 (83.1%) | 439 (84.2%) |
| Slight | 0 | 3 (5.7%) | 7 (13.2%) | 11 (20.8%) | 32 (60.4%) | 53 | |
| Medium | 1 (5.3%) | 2 (10.5%) | 3 (15.8%) | 5 (26.3%) | 8 (42.1%) | 19 | |
| Severe | 2 (20%) | 1 (10%) | 4 (40%) | 2 (20%) | 1 (10%) | 10 | |
| Total IPSS | 3 (3.6%) | 6 (7.3%) | 14 (17.1%) | 18 (18.3%) | 41 (50 %) | 82 (15.8%) | |
| Total | 5 (1%) | 11 (2.1%) | 23 (4.4%) | 76 (14.6%) | 406 (77.9%) | 521 (100%) | |
| Over 40 | Without IPSS | 1 (0.4%) | 5 (2%) | 26 (10.4%) | 71 (28.5%) | 146 (58.6%) | 249 (37.4%) |
| Slight | 14 (6.8%) | 21(10.2%) | 46 (22.3%) | 73 (35.4%) | 52 (25.2%) | 206 | |
| Medium | 16(13.7%) | 23 (19.7%) | 35 (31.6%) | 22 (18.9%) | 21 (17.9%) | 117 | |
| Severe | 25 (26.9%) | 30 (32.3%) | 17 (18.3%) | 19 (20.4%) | 2 (2.2%) | 93 | |
| Total IPSS | 55 (13.2%) | 74 (17.8%) | 98 (23.6%) | 114 (27.4%) | 75 (18%) | 416 (62.6%) | |
| Total | 56 (8.4%) | 79 (11.9%) | 124 (18.6%) | 185 (27.8%) | 221 (33.2%) | 665 | |
| Total | 61 | 90 | 147 | 261 | 627 | 1.186 |
It is clear from the table that no matter the patient’s age, the IPSS severity directly influences the severity of erectile dysfunction, but more obviously in those over 40. Thus, 20% of people up to 40 years old and 26.9% of those over 40 with severe IPSS will also have severe erectile dysfunction. At the same time, mild IPSS does not correlate with severe ED in the young, only 5.7% reporting a severe or moderate erectile dysfunction, compared to 17% of those over 40 years old.
Correlations between IIEF -5 variables score and IPSS total, according to the Pearson coefficient, showed an inversely proportional relationship (r = - 0.575, P 0.0001) between these parameters. An increased IPSS score leads to an IIEF-5 score decrease. Therefore, patients with advanced LUTS symptomatology manifested through IPSS increase will also have a more pronounced erectile dysfunction. The statistic significance is more evident in patients over 40 (Table 8).
Table 8.
Correlations between erectile dysfunction and IPSS score (1,186 patients)
| Age (years) | No. patients | Mean ± Standard Deviation | Correlation IPSS and IIFE-5 | ||
|---|---|---|---|---|---|
| IPSS | IIFE-5 | R | P | ||
| 18 – 39 | 521 | 3.65± 5.36 | 20.60±5.28 | - 0.153 | P < 0.05 |
| 40 – 49 | 271 | 8.7 ± 9.52 | 16.81±5.46 | - 0.587 | P < 0.001 |
| 50 – 64 | 287 | 12.47±8.49 | 13.9±5.84 | - 0.481 | P < 0.001 |
| 64 + | 107 | 18.9 ± 8.31 | 6.92±3.41 | - 0.210 | P < 0.001 |
| Total | 1186 | 13.25± 9.29 | 13.8 ±6.36 | - 0.575 | P < 0.001 |
Discussions
As it was mentioned in the introduction of this paper, LUTS prevalence studies, with or without correlations with erectile dysfunction, were performed in several countries. These publications appreciate the dependence of erectile dysfunction on LUTS symptomatology severity. At the same time, the data vary greatly from one country to another, probably depending on the socio-economic situation of the country. Thus, a Nigerian study realized on a sample of 658 men over 40 years of age determined only LUTS global prevalence, which was 59.1%, with 48.2% predominance of bladder filling symptoms comparative with other LUTS signs. Only half of the men suffering from LUTS searched for medical assistance, the latter being dependent on educational status [9].
In Gonsalez et al.’s study, conducted in Mexico on a sample of 1,041 men with an average age of 48.6 ± 14.5, only 11.8% men were asymptomatic, but 7.8% had a severe IPSS score, nocturia being present in 72.4% of people. At the same time, 63.2% people also reported the presence of erectile dysfunction [10].
The prevalence of moderate and severe LUTS in men from Hong Kong being under primary care was 36% and 36% respectively, and erectile dysfunction was found in 68%, including 28% with a severe form. We mention that it concerns the men who already suffered from a certain pathology, compared to our study, which is a population survey [11].
The population survey conducted in the Russian Federation showed the presence of LUTS symptomatology according to the IPSS score in 59.9% of males over 20 and the prevalence of erectile dysfunction of 48.9%. The LUTS symptomatology was more commonly associated with erectile dysfunction than high blood pressure or diabetes mellitus. [12] Song’s study, based on a sample of 1,644 men aged over 50, showed obvious direct correlations between LUTS and ED severity, so men with severe IPSS will and even slight IPSS will contribute to dysfunction appearance in about 85.7% [13.]
At the same time, the presence of erectile dysfunction can be a predictor of LUTS severity. Patients with severe LUTS often suffer from other pathologies, which are considered risk factors for erectile dysfunction, such as obesity, high blood pressure or metabolic syndrome [14].
The statistically significant correlations between LUTS and ED require comprehensive primary patient assessment for one of the above-mentioned pathologies including the use of IPSS and IIFE standardized questionnaires as well as complex diagnosis methods for simultaneous diagnosis of both. Taking into consideration that LUTS treatment can affect sexual function, sexual appetite, ejaculation and erection, primary examination of the patient is mandatory. On the other hand, [15] LUTS symptomatology presence has a significant impact on the quality of life, including the sexual one. On the other hand, most elderly patients consider their presence a part of the aging process and avoid addressing a doctor.
LUTS symptomatology may occur due to adenoma or prostate adenocarcinoma, or chronic prostatitis, requiring long-term treatment, sometimes altering erectile function. On the other hand, treatment can improve LUTS symptomatology and later the sexual function.
The sexual function should be evaluated in all men requiring LUTS treatment using validated questionnaires. It is also necessary to assess the presence of comorbidities and used medication, lifestyle and other risk factors [16][17].
Conclusions
LUTS and ED symptomatology have an increased prevalence among men in the Republic of Moldova, especially after the age of 40. Statistically significant correlations were demonstrated between these two pathologies. These correlations need to be taken into account both in establishing the diagnosis and in concomitant treatment.
ED total prevalence in the studied population was 47.1%, including mild - 22%, slightly-moderate - 12.4%, moderate - 7.6% and severe - 5.1%.
The overall prevalence of LUTS symptomatology, according to the IPSS score, was 42.9%, with significant variations in males up to 40 years old - 15.7% and over this age - 62.6% (p <0.05). LUTS presence correlates directly with erectile dysfunction prevalence, especially in men over the age of 40, where 82% of those with LUTS will also have ED.
References
- 1.Rosen R, Altwein J, Boyle P, Kirby R. Lower Urinary Tract Symptoms and Male Sexual Dysfunction: The Multinational Survey of the Aging Male (MSAM-7) European Urology. 2003;44(6):637–649. doi: 10.1016/j.eururo.2003.08.015. [DOI] [PubMed] [Google Scholar]
- 2.Rosen RC. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol. 2006 Jan;16(1):11–9. [PubMed] [Google Scholar]
- 3.Wein AJ, Coyne KS, Tubaro A, et al. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int 2009. 103(Suppl 3):33–41. doi: 10.1111/j.1464-410X.2009.08447.x. [DOI] [PubMed] [Google Scholar]
- 4.Seftel AD, De la Rosette J, Birt J, Porter V, Zartotsky V, Viktrup V. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. IJCP. 2013;67(1):32–45. doi: 10.1111/ijcp.12044. DOI: 10.1111/ijcp.12044. [DOI] [PubMed] [Google Scholar]
- 5.McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int. 2006;(Suppl 2):23–8. doi: 10.1111/j.1464-410X.2006.06102.x. Apr;97 discussion 44-5. [DOI] [PubMed] [Google Scholar]
- 6.Orabi H, Albersen M., Lue TF. Association of lower urinary tract symtoms and erectile dysfunction: pathophysiological aspects and implications for clinical management. Int J of Impot. 2011;23(3):99–108. doi: 10.1038/ijir.2011.14. [DOI] [PubMed] [Google Scholar]
- 7.Stief CG, Porst H, Neuser D. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008 Jun;53(6):1236–1244. doi: 10.1016/j.eururo.2008.01.075. Epub 2008 Feb. 4. [DOI] [PubMed] [Google Scholar]
- 8.Apostolidis A, Rantell A, Anding R, Kirschner-Hermanns R, Cardozo L. How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2. Neurourol Urodyn. 2017;36(4):869–875. doi: 10.1002/nau.23088. doi: 10.1002/nau.23088. [DOI] [PubMed] [Google Scholar]
- 9.Ojewola RW, Oridota ES, Balogun OS, Ogundare EO, Alabi TO. Lower Urinary Tract Symptoms: Prevalence, Perceptions, and Healthcare-Seeking Behavior amongst Nigerian Men. World J Mens Health. 2016;34(3):200–208. doi: 10.5534/wjmh.2016.34.3.200. doi: 10.5534/wjmh.2016.34.3.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Gonsalez-Sanchez B, Cendejas-Gomez J, Alejandro Rivera-Ramirez J., et al. doi: 10.1007/s00345-015-1703-4. The correlation between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED): results from a survey in males from Mexico City (MexiLUTS) World J Urol (2016) 34: 979. doi:10.1007/s00345-015-1703-4. [DOI] [PubMed] [Google Scholar]
- 11.Ngai KH, Kwong AS, Wong AS, Tsui WW. Erectile dysfunction and lower urinary tract symptoms: prevalence and risk factors in a Hong Kong primary care setting. Hong Kong Med J. 2013;19(4):311–6. doi: 10.12809/hkmj133770. doi: 10.12809/hkmj133770. [DOI] [PubMed] [Google Scholar]
- 12.Korneyevl A, Alexeeva TA, Al-Shukri SH, et al. Prevalence and risc factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men:analysis from a national population based multicenter study. Int I Impot Res. 2016;28(2):74–79. doi: 10.1038/ijir.2016.8. doi:10.1038/ijir.2016.8.Epub2016Feb11. [DOI] [PubMed] [Google Scholar]
- 13.Song Jian, Shao Qiang, Tian Ye, Chen Shan. Lower Urinary Tract Symptoms, Erectile Dysfunction, and Their Correlation in Men Aged 50 Years and Above: A Cross-Sectional Survey in Beijing, China. Med Sci Monit. 2014;20:2806–2810. doi: 10.12659/MSM.891180. doi:10.12659/MSM.891180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male. 2009;12(1):29–34. doi: 10.1080/13685530902777425. [DOI] [PubMed] [Google Scholar]
- 15.Gacci M, Eardley I, Giuliano F, et al. Criticla analysis of the relationship between sexual dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia. doi: 10.1016/j.eururo.2011.06.037. Eur Urol 2011. Nr.60 (4);809-25. doi:10.1016/j.eururo.2011.06.037. [DOI] [PubMed] [Google Scholar]
- 16.Jung J, Jae S, Kam S, Hyun J. Corelation between lower urinary tract symtoms(LUTS) and sexual Function in benign prostatic hyperplasia:Impact of tteatment of LUTS on sexual function. J Sex Med. 2009;6:2299–2304. doi: 10.1111/j.1743-6109.2009.01324.x. [DOI] [PubMed] [Google Scholar]
- 17.Mirone V, Sessa A, Giuliano F, Berges R, Kirby M, Moncada I. Current benign prostatic hyperplasia treatment: impact on sexual function and management of related sexual adverse events. Int J Clin Pract. 2011;65(9):1005–13. doi: 10.1111/j.1742-1241.2011.02731.x. doi: 10.1111/j.1742-1241.2011.02731.x. [DOI] [PubMed] [Google Scholar]